Research graph
References from RNA modifications and metabolism in cancer: Mechanisms, cross-talk and therapeutic implications. Local targets link to admitted publications; unresolved targets remain external evidence.
Transcriptome-wide analysis of roles for tRNA modifications in translational regulation
10.1016/j.molcel.2017.11.002 · 2017 · External reference
Deciphering RNA modifications at base resolution: from chemistry to biology
10.1093/bfgp/elaa024 · 2021 · External reference
Dynamic RNA modifications in gene expression regulation
10.1016/j.cell.2017.05.045 · 2017 · External reference
Macromolecular polymer based complexes: a diverse strategy for the delivery of nucleotides
10.2174/0109298665310091240809103048 · 2024 · External reference
Detecting RNA modifications in the epitranscriptome: predict and validate
10.1038/nrg.2016.169 · 2017 · External reference
Detection and quantification of 5moU RNA modification from direct RNA sequencing data
10.2174/0113892029288843240402042529 · 2024 · External reference
Ramifications of m⁶A modification on ncRNAs in cancer
10.2174/0113892029296712240405053201 · 2024 · External reference
RNA modification systems as therapeutic targets
2025 · External reference
Prediction of m⁶A and m⁵C at single-molecule resolution reveals a transcriptome-wide co-occurrence of RNA modifications
10.1038/s41467-024-47953-7 · 2024 · External reference
Theoretical framework and emerging challenges of lipid metabolism in cancer
10.1016/j.semcancer.2024.12.002 · 2025 · External reference
Potential therapies targeting nuclear metabolic regulation in cancer
10.1002/mco2.421 · 2023 · External reference
Leveraging cancer metabolism to translate into effective therapeutics
10.1016/j.semcancer.2025.12.003 · 2026 · External reference
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging
10.1016/j.semcancer.2025.02.003 · 2025 · External reference
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
10.1016/j.semcancer.2022.02.010 · 2022 · External reference
Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth
10.1038/s42255-022-00568-y · 2022 · External reference
Metabolism of amino acids in cancer
2020 · External reference
hnRNPL phase separation activates PIK3CB transcription and promotes glycolysis in ovarian cancer
10.1038/s41467-025-60115-7 · 2025 · External reference
Editorial: tumor metabolism: from molecular mechanisms to clinical application
10.3389/fcell.2023.1158467 · 2023 · External reference
Glucose-mediated N-glycosylation of SCAP Is Essential for SREBP-1 activation and tumor growth
10.1016/j.ccell.2015.09.021 · 2015 · External reference
Targeting SMOX for the treatment of hepatocellular carcinoma?
10.1016/j.clinre.2024.102429 · 2024 · External reference
Recent trends in development of novel therapeutics for modulation of 14-3-3 protein-protein interactions in diseases
10.2174/0109298665330728241025082011 · 2024 · External reference
RNA modification: mechanisms and therapeutic targets
10.1186/s43556-023-00139-x · 2023 · External reference
Epitranscriptome: Review of Top 25 Most-Studied RNA Modifications
10.3390/ijms232213851 · 2022 · External reference
Deciphering the pseudouridine nucleobase modification in human diseases: From molecular mechanisms to clinical perspectives
10.1002/ctm2.70190 · 2025 · External reference
Pseudouridine in a new era of RNA modifications
10.1038/cr.2014.143 · 2015 · External reference
Chemically modified tRNA enhances the translation capacity of mRNA rich in cognate codons
10.1038/s41467-025-62981-7 · 2025 · External reference
tRNA dysregulation and disease
10.1038/s41576-022-00501-9 · 2022 · External reference
RNA modifications modulate gene expression during development
10.1126/science.aau1646 · 2018 · External reference
RNA modifications in physiology and disease: towards clinical applications
10.1038/s41576-023-00645-2 · 2024 · External reference
Messenger RNA modifications: Form, distribution, and function
10.1126/science.aad8711 · 2016 · External reference
The Role of Noncoding RNA Pseudouridylation in Nuclear Gene Expression Events
10.3389/fbioe.2018.00008 · 2018 · External reference
Scintillation proximity assay for measurement of RNA methylation
10.1093/nar/gkn1038 · 2009 · External reference
Semi-quantitative detection of pseudouridine modifications and type I/II hypermodifications in human mRNAs using direct long-read sequencing
10.1038/s41467-023-35858-w · 2023 · External reference
The m¹A landscape on cytosolic and mitochondrial mRNA at single-base resolution
10.1038/nature24456 · 2017 · External reference
10.1038/s41698-026-01278-4
10.1038/s41698-026-01278-4 · External reference
A-to-I editing of coding and non-coding RNAs by ADARs
10.1038/nrm.2015.4 · 2016 · External reference
DirectRM: integrated detection of landscape and crosstalk between multiple RNA modifications using direct RNA sequencing
10.1038/s41467-025-64495-8 · 2025 · External reference
Mapping m(6)A at Individual-Nucleotide Resolution Using Crosslinking and Immunoprecipitation (miCLIP)
10.1007/978-1-4939-6807-7_5 · 2017 · External reference
10.1093/gpbjnl/qzag019
10.1093/gpbjnl/qzag019 · External reference
The epitranscriptome toolbox
10.1016/j.cell.2022.02.007 · 2022 · External reference
Integrative Analysis of CUT&Tag and RNA-Seq Data Through Bioinformatics: A Unified Workflow for Enhanced Insights
10.1007/978-1-0716-4071-5_13 · 2024 · External reference
Bioinformatics approaches for deciphering the epitranscriptome: Recent progress and emerging topics
10.1016/j.csbj.2020.06.010 · 2020 · External reference
Differential RNA methylation using multivariate statistical methods
10.1093/bib/bbab309 · 2022 · External reference
Role of main RNA modifications in cancer: N(6)-methyladenosine, 5-methylcytosine, and pseudouridine
10.1038/s41392-022-01003-0 · 2022 · External reference
Genetic and epigenetic defects of the RNA modification machinery in cancer
10.1016/j.tig.2022.10.004 · 2023 · External reference
The dynamic epitranscriptome: N⁶-methyladenosine and gene expression control, Nature reviews
2014 · External reference
Emerging Roles of RNA Methylation in Development
10.1021/acs.accounts.3c00448 · 2023 · External reference
N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism
10.1038/s41467-021-26718-6 · 2021 · External reference
The Mechanism and Latest Progress of m⁶A Methylation in the Progression of Pancreatic Cancer
10.7150/ijbs.104407 · 2025 · External reference
N(6) -methyladenosine Steers RNA Metabolism and Regulation in Cancer
10.1002/cac2.12161 · 2021 · External reference
O-GlcNAcylation determines the translational regulation and phase separation of YTHDF proteins
10.1038/s41556-023-01258-x · 2023 · External reference
METTL5-mediated 18S rRNA mA modification enhances ribosome assembly and ABA response in Arabidopsis
10.1002/imt2.70055 · 2025 · External reference
METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m⁶A-dependent manner
10.1038/s12276-020-00510-w · 2021 · External reference
N⁶-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer
10.1186/s13045-021-01204-0 · 2021 · External reference
Crosstalk between N⁶-methyladenosine modification and circular RNAs: current understanding and future directions
10.1186/s12943-021-01415-6 · 2021 · External reference
Mutual regulation between N⁶-methyladenosine (m⁶A) modification and circular RNAs in cancer: impacts on therapeutic resistance
10.1186/s12943-022-01620-x · 2022 · External reference
Biological roles of RNA m(5)C modification and its implications in Cancer immunotherapy
10.1186/s40364-022-00362-8 · 2022 · External reference
Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behavior
10.1038/s41467-021-24969-x · 2021 · External reference
mRNA turnover dynamics are affected by cell differentiation and loss of the cytosine methyltransferase Nsun2
10.1093/nar/gkaf995 · 2025 · External reference
NSUN5 Attenuates Renal Injury and Ferroptosis in Hyperuricaemic Nephropathy Through YBX2-Dependent Stabilisation of SCD1 m⁵C Methylation
2026 · External reference
m⁵C-Atlas: a comprehensive database for decoding and annotating the 5-methylcytosine (m⁵C) epitranscriptome
10.1093/nar/gkab1075 · 2022 · External reference
The Quiet Giant: Identification, Effectors, Molecular Mechanism, Physiological and Pathological Function in mRNA 5-methylcytosine Modification
10.7150/ijbs.101337 · 2024 · External reference
NOP2-mediated 5-methylcytosine modification of APOL1 messenger RNA activates PI3K-Akt and facilitates clear cell renal cell carcinoma progression
10.7150/ijbs.97503 · 2024 · External reference
Enhancer RNAs: mechanisms in transcriptional regulation and functions in diseases
10.1186/s12964-023-01206-0 · 2023 · External reference
Tet-mediated formation of 5-hydroxymethylcytosine in RNA
10.1021/ja505305z · 2014 · External reference
ALKBH1 is an RNA dioxygenase responsible for cytoplasmic and mitochondrial tRNA modifications
10.1093/nar/gkx354 · 2017 · External reference
Chemoproteomic Approaches to Studying RNA Modification-Associated Proteins
10.1021/acs.accounts.3c00450 · 2023 · External reference
Glycosylated queuosines in tRNAs optimize translational rate and post-embryonic growth
10.1016/j.cell.2023.10.026 · 2023 · External reference
Programmable RNA N(1) -Methyladenosine Demethylation by a Cas13d-Directed Demethylase
10.1002/anie.202105253 · 2021 · External reference
Evidence human FTO catalyses hydroxylation of N-methyladenosine without direct formation of a demethylated product contrasting with ALKBH5/2/3 and bacterial AlkB
10.1093/nar/gkaf813 · 2025 · External reference
Combining Nanopore direct RNA sequencing with genetics and mass spectrometry for analysis of T-loop base modifications across 42 yeast tRNA isoacceptors
10.1093/nar/gkae796 · 2024 · External reference
YTHDC1 cooperates with the THO complex to prevent RNA-damage-induced DNA breaks
10.1016/j.molcel.2025.02.003 · 2025 · External reference
The potential role of N⁷-methylguanosine (m⁷G) in cancer
10.1186/s13045-022-01285-5 · 2022 · External reference
Jr., The mechanism of mRNA cap recognition
10.1038/s41586-024-08304-0 · 2025 · External reference
Chemical circularization of in vitro transcribed RNA for exploring circular mRNA design
10.1038/s41467-025-61775-1 · 2025 · External reference
Perturbation of METTL1-mediated tRNA N7- methylguanosine modification induces senescence and aging
10.1038/s41467-024-49796-8 · 2024 · External reference
18S rRNA methyltransferases DIMT1 and BUD23 drive intergenerational hormesis
10.1016/j.molcel.2023.08.014 · 2023 · External reference
Direct epitranscriptomic regulation of mammalian translation initiation through N⁴-acetylcytidine
10.1016/j.molcel.2022.05.016 · 2022 · External reference
NAT10-dependent N(4)-acetylcytidine modification mediates PAN RNA stability, KSHV reactivation, and IFI16-related inflammasome activation
10.1038/s41467-023-42135-3 · 2023 · External reference
Recent advances in the potential role of RNA N⁴-acetylcytidine in cancer progression
10.1186/s12964-023-01417-5 · 2024 · External reference
Transfer RNA acetylation regulates in vivo mammalian stress signaling
10.1126/sciadv.ads2923 · 2025 · External reference
Probing small ribosomal subunit RNA helix 45 acetylation across eukaryotic evolution
10.1093/nar/gkac404 · 2022 · External reference
Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression
2023 · External reference
Quantitative profiling of pseudouridylation landscape in the human transcriptome
10.1038/s41589-023-01304-7 · 2023 · External reference
Quantitative RNA pseudouridine maps reveal multilayered translation control through plant rRNA, tRNA and mRNA pseudouridylation
10.1038/s41477-024-01894-7 · 2025 · External reference
Regulation of translation by ribosomal RNA pseudouridylation
10.1126/sciadv.adg8190 · 2023 · External reference
A Ψ-Ψ codon-anticodon pairing in nonsense suppression and translational recoding
10.1038/s41589-025-02025-9 · 2026 · External reference
A comprehensive tRNA pseudouridine map uncovers targets dependent on human stand-alone pseudouridine synthases
10.1038/s41556-025-01803-w · 2025 · External reference
The human pseudouridine synthase PUS7 recognizes RNA with an extended multi-domain binding surface
10.1093/nar/gkab934 · 2021 · External reference
Quantitative analysis of small RNA pseudouridylation reveals interplay of PUS enzymes in tRNA anticodon stem-loop
2026 · External reference
Absolute quantitative and base-resolution sequencing reveals comprehensive landscape of pseudouridine across the human transcriptome
10.1038/s41592-024-02439-8 · 2024 · External reference
DirectRMDB: a database of post-transcriptional RNA modifications unveiled from direct RNA sequencing technology
10.1093/nar/gkac1061 · 2022 · External reference
RNA modifications detection by comparative Nanopore direct RNA sequencing
10.1038/s41467-021-27393-3 · 2021 · External reference
Understanding the Intersections between Metabolism and Cancer Biology
10.1016/j.cell.2016.12.039 · 2017 · External reference
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
10.1016/j.addr.2020.07.013 · 2020 · External reference
Metabolic pathways promoting cancer cell survival and growth
10.1038/ncb3124 · 2015 · External reference
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate
10.1016/j.ccr.2012.02.014 · 2012 · External reference
The Warburg Effect is the result of faster ATP production by glycolysis than respiration
10.1073/pnas.2409509121 · 2024 · External reference
Hyperbaric oxygen augments Doxil antitumor efficacy by reducing tumor-induced lactate
10.1016/j.jconrel.2025.114181 · 2025 · External reference
Glutamine Metabolism in Cancer: Understanding the Heterogeneity
10.1016/j.trecan.2017.01.005 · 2017 · External reference
The Warburg Effect: How Does it Benefit Cancer Cells?
10.1016/j.tibs.2015.12.001 · 2016 · External reference
The hallmarks of cancer metabolism: Still emerging
10.1016/j.cmet.2022.01.007 · 2022 · External reference
The return of metabolism: biochemistry and physiology of the pentose phosphate pathway
10.1111/brv.12140 · 2015 · External reference
Regulation of glucose metabolism from a liver-centric perspective
10.1038/emm.2015.122 · 2016 · External reference
Lactate in the tumour microenvironment: From immune modulation to therapy
10.1016/j.ebiom.2021.103627 · 2021 · External reference
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
10.1186/s12943-024-02119-3 · 2024 · External reference
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
10.1158/0008-5472.can-20-3242 · 2021 · External reference
Lipid metabolism in cancer: New perspectives and emerging mechanisms
10.1016/j.devcel.2021.04.013 · 2021 · External reference
Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma
10.1038/s41419-019-1532-2 · 2019 · External reference
Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer
10.1016/j.cmet.2019.11.010 · 2020 · External reference
Fatty Acid Oxidation Supports Lymph Node Metastasis of Cervical Cancer via Acetyl-CoA-Mediated Stemness
2024 · External reference
CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma
10.1038/s41419-022-04730-y · 2022 · External reference
Fatty acid oxidation: An emerging facet of metabolic transformation in cancer
10.1016/j.canlet.2018.08.006 · 2018 · External reference
Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine
10.15252/embj.201696151 · 2017 · External reference
Glutaminase isoenzymes in the metabolic therapy of cancer
10.1016/j.bbcan.2018.07.007 · 2018 · External reference
New aspects of amino acid metabolism in cancer
10.1038/s41416-019-0620-5 · 2020 · External reference
The emerging role and targetability of the TCA cycle in cancer metabolism
10.1007/s13238-017-0451-1 · 2018 · External reference
Blocking the TCA Cycle in Cancer Cells Potentiates CD36+ T-cell-Mediated Antitumor Immunity by Suppressing ER Stress-Associated THBS2 Signaling
10.1158/0008-5472.can-24-3477 · 2025 · External reference
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
10.1016/j.ccr.2010.01.020 · 2010 · External reference
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
10.1038/nature12040 · 2013 · External reference
Nucleotide metabolism: a pan-cancer metabolic dependency
10.1038/s41568-023-00557-7 · 2023 · External reference
Nucleotide deficiency promotes genomic instability in early stages of cancer development
10.1016/j.cell.2011.03.044 · 2011 · External reference
Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer
10.1016/j.gendis.2022.11.022 · 2024 · External reference
DHODH and cancer: promising prospects to be explored
10.1186/s40170-021-00250-z · 2021 · External reference
Spatial colocalization and functional link of purinosomes with mitochondria
10.1126/science.aac6054 · 2016 · External reference
MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis
10.1038/nature14351 · 2015 · External reference
AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation
10.1126/science.1172156 · 2009 · External reference
Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer
10.1016/j.apsb.2023.12.003 · 2024 · External reference
The Warburg effect: Saturation of mitochondrial NADH shuttles triggers aerobic lactate fermentation
10.1016/j.molcel.2022.08.004 · 2022 · External reference
AMPK-HIF-1α signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth
2023 · External reference
Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells
10.1172/jci178617 · 2024 · External reference
A non-canonical tricarboxylic acid cycle underlies cellular identity
10.1038/s41586-022-04475-w · 2022 · External reference
Mitochondrial glutamine import sustains electron transport chain integrity independently of glutaminolysis in cancer
10.1016/j.molcel.2025.12.001 · 2026 · External reference
Mitochondrial metabolism-mediated redox regulation in cancer progression
10.1016/j.redox.2021.101870 · 2021 · External reference
Targeting de novo lipid synthesis induces lipotoxicity and impairs DNA damage repair in glioblastoma mouse models
10.1126/scitranslmed.abq6288 · 2023 · External reference
ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma
10.26508/lsa.202201400 · 2023 · External reference
Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities
10.1186/s12944-023-01881-5 · 2023 · External reference
Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma
2024 · External reference
Glutamine addiction in tumor cell: oncogene regulation and clinical treatment
10.1186/s12964-023-01449-x · 2024 · External reference
Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment
10.1097/cm9.0000000000002758 · 2024 · External reference
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
10.1038/s43018-023-00647-3 · 2024 · External reference
m(6)A-dependent glycolysis enhances colorectal cancer progression
10.1186/s12943-020-01190-w · 2020 · External reference
RNA N(6)-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m(6)A-GLUT1-mTORC1 Axis and Is a Therapeutic Target
10.1053/j.gastro.2020.11.013 · 2021 · External reference
LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N⁶-methyladenosine modification on GLUT1 and PKM2
2023 · External reference
The m⁶A modification-mediated positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma
10.7150/ijbs.86658 · 2024 · External reference
N(6)-methyladenosine-modified SRPK1 promotes aerobic glycolysis of lung adenocarcinoma via PKM splicing
10.1186/s11658-024-00622-5 · 2024 · External reference
METTL3-stabilized lncRNA SNHG7 accelerates glycolysis in prostate cancer via SRSF1/c-Myc axis
10.1016/j.yexcr.2022.113149 · 2022 · External reference
Linc-UROD stabilizes ENO1 and PKM to strengthen glycolysis, proliferation and migration of pancreatic cancer cells
10.1016/j.tranon.2022.101583 · 2023 · External reference
N⁶-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer
2022 · External reference
Up-regulation of m(6)A writer METTL14 inhibits tumorigenesis by suppressing glycolysis in colorectal cancer
10.1186/s12885-025-13532-2 · 2025 · External reference
METTL14-mediated m⁶A mRNA modification of G6PD promotes lung adenocarcinoma
10.1038/s41420-024-02133-w · 2024 · External reference
Glycolysis and tumor progression promoted by the m(6)A writer VIRMA via m(6)A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma
10.1016/j.canlet.2024.216840 · 2024 · External reference
FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N⁶-methyladenosine-dependent manner
2022 · External reference
The essential roles of m(6)A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma
2022 · External reference
ALKBH5-Mediated m⁶A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer
10.1158/0008-5472.can-22-0800 · 2022 · External reference
USF1-mediated ALKBH5 stabilizes FLII mRNA in an m⁶A-YTHDF2-dependent manner to repress glycolytic activity in prostate adenocarcinoma
10.1002/mc.23609 · 2023 · External reference
ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m⁶A-CK2α-Mediated Glycolysis
10.1016/j.omtn.2020.10.031 · 2021 · External reference
UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis
2022 · External reference
m(6)A methyltransferase KIAA1429 accelerates oral squamous cell carcinoma via regulating glycolysis and ferroptosis
10.1016/j.tranon.2023.101745 · 2023 · External reference
YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis
10.1038/s41419-022-04711-1 · 2022 · External reference
Histone lactylation-driven YTHDF2 promotes non-small cell lung cancer cell glycolysis and stemness by recognizing m⁶A modification of SFRP2
10.1016/j.bcp.2025.117097 · 2025 · External reference
METTL14-mediated m⁶A modification of ETV4 inhibits tumor development in colorectal cancer
2025 · External reference
N(6)-methyladenosine reader YTHDF3 contributes to the aerobic glycolysis of osteosarcoma through stabilizing PGK1 stability
10.1007/s00432-022-04337-y · 2023 · External reference
N(6)-methyladenosine (m(6)A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner
10.1016/j.yexcr.2022.113176 · 2022 · External reference
IGF2BP1 accelerates the aerobic glycolysis to boost its immune escape in hepatocellular carcinoma microenvironment
10.3389/fimmu.2024.1480834 · 2024 · External reference
WWP2 overexpression inhibits the antitumor effects of doxorubicin in hepatocellular carcinoma
10.1002/cbin.11856 · 2022 · External reference
m⁶A reader IGF2BP2 mediates paclitaxel resistance in esophageal squamous cell carcinoma via FOXM1 mRNA stabilization
10.3892/or.2025.9002 · 2025 · External reference
m(6)A reader IGF2BP2-stabilized CASC9 accelerates glioblastoma aerobic glycolysis by enhancing HK2 mRNA stability
10.1038/s41420-021-00674-y · 2021 · External reference
NSUN2-tRNA(Val-CAC)-axis-regulated codon-biased translation drives triple-negative breast cancer glycolysis and progression
10.1186/s11658-025-00781-z · 2025 · External reference
The NSUN2-YBX1 axis enhances 5-Methylcytosine modification to facilitate NPM1-mediated nuclear translocation of PKM2, augmenting the Warburg effect and promoting nasopharyngeal carcinoma progression in a mouse model
2025 · External reference
NSUN2 contributes to the RB malignant progression and Glycolysis by mediating the m⁵C methylation modification of HKDC1
10.1007/s10863-025-10062-1 · 2025 · External reference
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2-mediated increase of SOAT2 RNA methylation
10.1002/cac2.70023 · 2025 · External reference
NSUN5 accelerates the progression of liver hepatocellular carcinoma by m⁵C-EFNA3-mediated glycolysis
10.1186/s12885-025-14714-8 · 2025 · External reference
NOP2-mediated m⁵C Modification of c-Myc in an EIF3A-Dependent Manner to Reprogram Glucose Metabolism and Promote Hepatocellular Carcinoma Progression
2023 · External reference
The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer
10.1002/cac2.12158 · 2021 · External reference
10.2174/0113862073392269250825105059
10.2174/0113862073392269250825105059 · External reference
RNA m(1)A methylation regulates glycolysis of cancer cells through modulating ATP5D
10.1073/pnas.2119038119 · 2022 · External reference
ALKBH3-regulated m(1)A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
10.1016/j.apsb.2025.04.018 · 2025 · External reference
N⁷-methylguanosine regulatory genes well represented by METTL1 define vastly different prognostic, immune and therapy landscapes in adrenocortical carcinoma
2023 · External reference
METTL1 mediates PKM m⁷G modification to regulate CD155 expression and promote immune evasion in colorectal cancer
10.1186/s12967-024-05991-1 · 2024 · External reference
METTL1 drives glioma progression by promoting N⁷-methylguanosine (m⁷G) modification of glycolysis-related enzyme PGK1
10.1016/j.prp.2025.156174 · 2025 · External reference
METTL1 mediates m⁷G modification of PFKFB3 mRNA to promote radioresistance in esophageal cancer by affecting glycolytic metabolism
10.1016/j.prp.2025.156102 · 2025 · External reference
Role of NAT10-mediated ac(4)C acetylation of ENO1 mRNA in glycolysis and apoptosis in non-small cell lung cancer cells
10.1186/s12890-024-03463-2 · 2025 · External reference
NAT10 promotes glycolysis and cell stemness of ovarian cancer cells via ac⁴C acetylation of PGAM1 mRNA
2025 · External reference
NAT10-mediated N4-acetylcytosine modification promotes the progression of retinoblastoma by improving the HK1 mRNA stability to enhance glycolysis
2025 · External reference
NAT10 contributes to the progression of multiple myeloma through ac⁴C modification of GPR37
2025 · External reference
N⁴-acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/HIF-1α Positive Feedback Loop
2023 · External reference
NAT10/ac⁴C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction
2024 · External reference
NAT10 mediated ac⁴C acetylation driven m(6)A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma
10.1186/s12964-023-01321-y · 2024 · External reference
Pseudouridine as a novel biomarker in prostate cancer
10.1016/j.urolonc.2020.06.026 · 2021 · External reference
The functions and mechanisms of RNA modification in prostate: Current status and future perspectives
2024 · External reference
PUS7 promotes the progression of pancreatic cancer by interacting ANLN to activate MYC pathway
10.1007/s11010-025-05267-2 · 2025 · External reference
Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat
10.1038/s41392-020-00235-2 · 2020 · External reference
The METTL14-YTHDF1-SAP30 Axis Promotes Glycolysis and Oxaliplatin Resistance in Colorectal Adenocarcinoma via m⁶A Modification
10.1111/jgh.16988 · 2025 · External reference
KIAA1429 increases FOXM1 expression through YTHDF1-mediated m⁶A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma
10.1007/s10565-024-09904-2 · 2024 · External reference
lncRNA miR4458HG modulates hepatocellular carcinoma progression by activating m⁶A-dependent glycolysis and promoting the polarization of tumor-associated macrophages
10.1007/s00018-023-04741-8 · 2023 · External reference
Integrative multi-omics reveal NSUN2 facilitates glycolysis and histone lactylation-driven immune evasion in renal carcinoma
10.1038/s41435-025-00336-4 · 2025 · External reference
Integrative proteomics and m⁶A microarray analyses of the signatures induced by METTL3 reveals prognostically significant in gastric cancer by affecting cellular metabolism
10.3389/fonc.2022.996329 · 2022 · External reference
FOXO6, Stabilized by METTL3-Mediated m⁶A Modification, Accelerates Polycystic Ovary Syndrome Progression by Transcriptional Activation of TXNIP
2025 · External reference
METTL3-mediated NFAT5 Upregulation Promotes Cervical Cancer Progression Through Enhancing the Mitochondrial Function by Transcriptional Regulation of PRDX1
10.1002/jbt.70162 · 2025 · External reference
Targeting fat mass and obesity-associated protein mitigates human colorectal cancer growth in vitro and in a murine model
10.3389/fonc.2023.1087644 · 2023 · External reference
Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer
10.1158/0008-5472.can-22-3059 · 2023 · External reference
YTHDF2 drives oral squamous cell carcinoma progression via m(6)A-dependent degradation of MTUS1/ATIP1 mRNA and mitochondrial dysregulation
10.1016/j.cellsig.2025.112145 · 2025 · External reference
NSUN2-mediated cytosine-5 methylation of FSP1 protects acute myeloid leukemia cells from ferroptosis
10.1186/s12943-025-02394-8 · 2025 · External reference
m⁵C-modified circRREB1 promotes lung cancer progression by inducing mitophagy
2025 · External reference
NSUN4-mediated m⁵C modification of circERI3 promotes lung cancer development by altering mitochondrial energy metabolism
10.1016/j.canlet.2024.217266 · 2024 · External reference
Metabolic reprogramming driven by METTL1-mediated tRNA m⁷G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma
2024 · External reference
PUS1 May Be a Potential Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma
2023 · External reference
YTHDF1-enhanced iron metabolism depends on TFRC m(6)A methylation
10.7150/thno.51231 · 2020 · External reference
N(6)-methyladenosine (m(6)A) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis
10.7717/peerj.14591 · 2023 · External reference
Identifying prognostic characteristics of m⁶A-related glycolysis gene and predicting the immune infiltration landscape in bladder cancer
10.1186/s12935-023-03160-w · 2023 · External reference
The m⁶A revolution: transforming tumor immunity and enhancing immunotherapy outcomes
10.1186/s13578-025-01368-z · 2025 · External reference
The role of RNA methylation in tumor immunity and its potential in immunotherapy
10.1186/s12943-024-02041-8 · 2024 · External reference
N(7)-methylguanosine tRNA modification promotes gastric cancer progression by activating SDHAF4-dependent mitochondrial oxidative phosphorylation
10.1016/j.canlet.2025.217566 · 2025 · External reference
Progression of m(6)A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming
10.1038/s41420-024-02092-2 · 2024 · External reference
The inhibition of YTHDF3/m(6)A/LRP6 reprograms fatty acid metabolism and suppresses lymph node metastasis in cervical cancer
10.7150/ijbs.87203 · 2024 · External reference
Histone lactylation-driven YTHDC1 promotes hepatocellular carcinoma progression via lipid metabolism remodeling
2024 · External reference
METTL14 promotes lipid metabolism reprogramming and sustains nasopharyngeal carcinoma progression via enhancing m(6)A modification of ANKRD22 mRNA
10.1002/ctm2.1766 · 2024 · External reference
ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m⁶A-IGF2BP2-dependent manner
10.1186/s12967-023-04578-6 · 2023 · External reference
m⁶A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer
10.1186/s13578-022-00798-3 · 2022 · External reference
m(6)A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1
10.3389/fonc.2020.553045 · 2020 · External reference
Cholesterol homeostasis confers glioma malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR
10.1093/neuonc/noad233 · 2024 · External reference
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma
10.1038/s41467-020-20379-7 · 2021 · External reference
METTL16 Promotes Lipid Metabolic Reprogramming and Colorectal Cancer Progression
10.7150/ijbs.105391 · 2025 · External reference
Harnessing m(6)A-regulated cholesterol biosynthesis helps impede tumor burden and stemness in high-garde serous ovarian carcinoma mesenchymal phenotype
10.1186/s10020-025-01413-0 · 2025 · External reference
Stabilization of SQLE mRNA by WTAP/FTO/IGF2BP3-dependent manner in HGSOC: implications for metabolism, stemness, and progression
10.1038/s41419-024-07257-6 · 2024 · External reference
IGF2BP3/ESM1/KLF10/BECN1 positive feedback loop: a novel therapeutic target in ovarian cancer via lipid metabolism reprogramming
10.1038/s41419-025-07571-7 · 2025 · External reference
CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m⁵C modification of ACC1 mRNA
10.1038/s41418-023-01223-z · 2023 · External reference
NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m(5)C methylation
10.1038/s41419-023-05646-x · 2023 · External reference
tRNA m¹A modification regulates cholesterol biosynthesis to promote antitumor immunity of CD8+ T cells
10.1084/jem.20240559 · 2025 · External reference
From palmitoylation to cholesterol metabolism: The hidden mechanism of lung tumorigenesis
10.1016/j.cellsig.2026.112497 · 2026 · External reference
NAT10: An RNA cytidine transferase regulates fatty acid metabolism in cancer cells
10.1002/ctm2.1045 · 2022 · External reference
Exosomal NAT10 from esophageal squamous cell carcinoma cells modulates macrophage lipid metabolism and polarization through ac⁴C modification of FASN
10.1016/j.tranon.2024.101934 · 2024 · External reference
N¹-methyladenosine RNA methylation patterns are associated with an increased risk to biochemical recurrence in prostate cancer and serve as a potential novel biomarker for patient stratification
2024 · External reference
The m⁶A reader IGF2BP2 promotes pancreatic cancer progression through the m⁶A-SLC1A5-mTORC1 axis
10.1186/s12935-025-03736-8 · 2025 · External reference
The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia
10.1016/j.ccell.2022.10.004 · 2022 · External reference
The m(6)A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor
10.1073/pnas.2000516117 · 2020 · External reference
METTL3-mediated m(6)A methylation of SLC38A1 stimulates cervical cancer growth
10.1016/j.bbrc.2024.150039 · 2024 · External reference
Epigenetic Activation of PTCD3 Promotes CRC Glutamine Metabolism and Metastasis via IGF2BP2-Mediated SLC38A2 m⁶A Modification
2025 · External reference
Cancer-associated fibroblasts-derived exosomal METTL3 promotes the proliferation, invasion, stemness and glutaminolysis in non-small cell lung cancer cells by eliciting SLC7A5 m⁶A modification
10.1007/s13577-024-01056-z · 2024 · External reference
NSUN2 Promotes the Growth, Metastasis and Glutamine Metabolism of Non-Small Cell Lung Cancer
2025 · External reference
Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism
10.1016/j.omto.2021.01.001 · 2021 · External reference
YTHDF1 regulates GID8-mediated glutamine metabolism to promote colorectal cancer progression in m⁶A-dependent manner
10.1016/j.canlet.2024.217186 · 2024 · External reference
Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways
10.1016/j.canlet.2024.217263 · 2024 · External reference
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression
2021 · External reference
WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinoma
10.34133/cancomm.0005 · 2026 · External reference
IGF2BP3-mediated regulation of GLS and GLUD1 gene expression promotes treg-induced immune escape in human cervical cancer
2023 · External reference
NSUN5 promotes cholangiocarcinoma progression by enhancing GLS mRNA stabilization
10.1007/s00432-025-06163-4 · 2025 · External reference
MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development
10.1158/0008-5472.can-24-1102 · 2024 · External reference
DKC1-mediated pseudouridylation of rRNA targets hnRNP A1 to sustain IRES-dependent translation and ATF4-driven metabolic adaptation
10.1126/sciadv.adv9401 · 2025 · External reference
Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition
10.7150/thno.60028 · 2021 · External reference
m(6)A RNA methyltransferase METTL16 induces Cr(VI) carcinogenesis and lung cancer development through glutamine biosynthesis and GLUL expression
10.1016/j.jhazmat.2024.136093 · 2024 · External reference
MYLK-AS1 enhances glutamine metabolism to promote EGFR inhibitor resistance in non-small cell lung cancer
10.1158/0008-5472.can-23-3748 · 2025 · External reference
Intertwined regulation between RNA m(6)A modification and cancer metabolism
10.1016/j.cellin.2022.100075 · 2023 · External reference
Regulations of m(6)A and other RNA modifications and their roles in cancer
10.1007/s11684-024-1064-8 · 2024 · External reference
Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m 6 A-mediated epitranscriptomic regulation
10.1097/hep.0000000000000420 · 2023 · External reference
Function and prognostic value of N⁶-methyladenosine-modified RNAs in lung adenocarcinoma
10.1002/jgm.3454 · 2023 · External reference
Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer
10.3389/fmed.2023.1193133 · 2023 · External reference
Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer
10.20892/j.issn.2095-3941.2025.0444 · 2026 · External reference
Landscape analysis of m⁵C modification regulators unveils DNMT1-mediated dysregulated pyrimidine metabolism in hepatocellular carcinoma
10.1186/s13148-025-01956-3 · 2025 · External reference
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
10.1016/j.celrep.2023.113016 · 2023 · External reference
Global Co-regulatory Cross Talk Between m(6)A and m(5)C RNA Methylation Systems Coordinate Cellular Responses and Brain Disease Pathways
10.1007/s12035-024-04555-0 · 2025 · External reference
Comprehensive mapping of RNA modification dynamics and crosstalk via deep learning and nanopore direct RNA-sequencing
10.1038/s41467-026-68419-y · 2026 · External reference
Integrative analysis of nanopore direct RNA sequencing data reveals a global impact of pseudouridylation on m(6)A and m(5)C modifications
10.1038/s41698-026-01278-4 · 2026 · External reference
TROP2 translation mediated by dual m(6)A/m(7)G RNA modifications promotes bladder cancer development
10.1016/j.canlet.2023.216246 · 2023 · External reference
YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies
10.1016/j.cell.2024.11.007 · 2025 · External reference
Differential m(6)A, m(6)A(m), and m(1)A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm
10.1016/j.molcel.2018.08.011 · 2018 · External reference
Structural insights into FTO's catalytic mechanism for the demethylation of multiple RNA substrates
10.1073/pnas.1820574116 · 2019 · External reference
m(1)A and m(6)A modifications function cooperatively to facilitate rapid mRNA degradation
10.1016/j.celrep.2022.111317 · 2022 · External reference
WTAP Mediated m⁶A Modification Stabilizes PDIA3P1 and Promotes Tumor Progression Driven by Histone Lactylation in Esophageal Squamous Cell Carcinoma
2025 · External reference
m(6) A transferase KIAA1429-stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1
10.1002/iub.2545 · 2021 · External reference
The lncRNA DAMER selectively guides m⁶A-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer
10.1038/s41556-026-01905-z · 2026 · External reference
N⁶-methyladenosine Modification of circIST1 Promotes Hypoxia-Inducible Factor α-mediated Glycolysis and Progression in Hepatocellular Carcinoma
10.1002/mco2.70577 · 2026 · External reference
N⁴-acetylcytidine modification of LINC02802 promotes non-small cell lung cancer progression by modulating mitochondrial NAD+/NADH ratio
10.7150/ijbs.116639 · 2025 · External reference
m⁶A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC
2025 · External reference
Identification of N(6)-methyladenosine-related lncRNAs for patients with primary glioblastoma
10.1007/s10143-020-01238-x · 2021 · External reference
N⁶-methyladenosine modification activates the serine synthesis pathway to mediate therapeutic resistance in liver cancer
10.1016/j.ymthe.2024.10.025 · 2024 · External reference
Metformin counteracts lipid accumulation and cell proliferation in hepatocellular carcinoma via regulating METTL3-mediated m(6)A methylation
10.1080/15384101.2026.2665248 · 2026 · External reference
Energy Stress-Induced circEPB41(2) Promotes Lipogenesis in Hepatocellular Carcinoma
10.1158/0008-5472.can-24-1630 · 2025 · External reference
N⁶-methyladenosine modification and metabolic reprogramming of digestive system malignancies
10.1016/j.canlet.2022.215815 · 2022 · External reference
Modulation of host N⁶-methyladenosine modification by gut microbiota in colorectal cancer
10.3748/wjg.v30.i38.4175 · 2024 · External reference
N⁶-methyladenosine RNA methylation, a new hallmark of metabolic reprogramming in the immune microenvironment
10.3389/fimmu.2024.1464042 · 2024 · External reference
Reprogramming cysteine metabolism via METTL14-SLC7A11 axis promotes the progression of NAFLD and hepatocellular carcinoma
10.1016/j.lfs.2025.123965 · 2025 · External reference
Metabolo-epigenetic interplay provides targeted nutritional interventions in chronic diseases and ageing
10.3389/fonc.2023.1169168 · 2023 · External reference
S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy
10.3390/cancers17030535 · 2025 · External reference
PRPS2 enhances RNA m(6)A methylation by stimulating SAM synthesis through enzyme-dependent and independent mechanisms
10.1038/s41467-025-59119-0 · 2025 · External reference
Unveiling the methionine cycle: a key metabolic signature and NR4A2 as a methionine-responsive oncogene in esophageal squamous cell carcinoma
10.1038/s41418-024-01285-7 · 2024 · External reference
The AHCY-adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesis
10.1038/s41422-025-01213-5 · 2026 · External reference
Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-Talk
10.4049/immunohorizons.2200086 · 2022 · External reference
Metabolic Coordination of Cell Fate by α-Ketoglutarate-Dependent Dioxygenases
10.1016/j.tcb.2020.09.010 · 2021 · External reference
Dysregulation of 2-oxoglutarate-dependent dioxygenases by hyperglycaemia: does this link diabetes and vascular disease?
10.1186/s13148-020-00848-y · 2020 · External reference
Alpha-ketoglutarate protects against myocardial infarction via FTO-mediated anti-inflammatory macrophage activation
10.1007/s00395-025-01135-8 · 2025 · External reference
Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma
10.1093/narcan/zcae004 · 2024 · External reference
Oncometabolite D-2HG drives tumor metastasis and protumoral macrophage polarization by targeting FTO/m(6)A/ANGPTL4/integrin axis in triple-negative breast cancer
2025 · External reference
The immune response to RNA suppresses nucleic acid synthesis by limiting ribose 5-phosphate
10.1038/s44318-024-00100-w · 2024 · External reference
D-ribose metabolic disorder and diabetes mellitus
10.1007/s11033-023-09076-y · 2024 · External reference
Metabolic Ink Lactate Modulates Epigenomic Landscape: A Concerted Role of Pro-tumor Microenvironment and Macroenvironment During Carcinogenesis
10.2174/1566524020666200521075252 · 2021 · External reference
Potential of lactylation as a therapeutic target in cancer treatment (Review)
10.3892/mmr.2025.13456 · 2025 · External reference
Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer
10.1038/s41467-023-42025-8 · 2023 · External reference
Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m⁶A-dependent KDM6B decay in bladder cancer
10.1016/j.canlet.2026.218282 · 2026 · External reference
Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m⁶A-Modification Promotes Lenvatinib Resistance in HCC
2024 · External reference
Lactylation-driven NSUN2-mediated RNA m⁵C modification promotes perineural invasion in pancreatic cancer
10.7150/thno.122294 · 2026 · External reference
Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development
10.1016/j.cmet.2025.07.008 · 2025 · External reference
Metabolic Control of m(6)A RNA Modification
10.3390/metabo11020080 · 2021 · External reference
Functions of N⁶-methyladenosine in cancer metabolism: from mechanism to targeted therapy
10.1186/s40364-023-00483-8 · 2023 · External reference
m⁶A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges
2025 · External reference
m⁵C RNA modification in colorectal cancer: mechanisms and therapeutic targets
10.1186/s12967-025-06985-3 · 2025 · External reference
N(6)-Methyladenosine RNA Modification: An Emerging Immunotherapeutic Approach to Turning Up Cold Tumors
10.3389/fcell.2021.736298 · 2021 · External reference
Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target
10.4251/wjgo.v17.i5.104076 · 2025 · External reference
Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material
10.3390/pharmaceutics13040544 · 2021 · External reference
Effect, Mechanism, and Applications of Coding/Non-Coding RNA m⁶A Modification in Tumor Microenvironment
10.3389/fcell.2021.711815 · 2021 · External reference
Non-Coding RNA m⁶A Modification in Cancer: Mechanisms and Therapeutic Targets
2021 · External reference
Targeting the m⁶A RNA Modification Pathway Blocks SARS-CoV-2 and HCoV-OC43 Replication
10.1101/gad.348320.121 · 2021 · External reference
N⁶-methyladenosine Links RNA Metabolism to Cancer Progression
10.1038/s41419-017-0129-x · 2018 · External reference
The Emerging Roles of RNA m⁶A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance
10.1158/0008-5472.can-20-4107 · 2021 · External reference
Epitranscriptomic advances in normal and malignant hematopoiesis
10.1038/s41375-025-02765-6 · 2025 · External reference
Main N⁶-methyladenosine Readers: YTH Family Proteins in Cancers
2021 · External reference
The Role of Insulin-Like Growth Factor 2 mRNA-binding Proteins (IGF2BPs) as M<sup>6</Sup>A Readers in Cancer
10.7150/ijbs.70458 · 2022 · External reference
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia
10.1016/j.ccell.2019.03.006 · 2019 · External reference
FTO-mediated Autophagy Promotes Progression of Clear Cell Renal Cell Carcinoma via Regulating SIK2 mRNA Stability
10.7150/ijbs.77774 · 2022 · External reference
A Rhein-Based Rh(III) Arene Complex With Anti-tumor Cell Proliferative Activity Inhibits RNA Demethylase FTO
10.1002/cjoc.202100901 · 2022 · External reference
Targeted Inhibition of m⁶A Demethylase FTO by FB23 Attenuates Allergic Inflammation in the Airway Epithelium
10.1096/fj.202400545r · 2024 · External reference
RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy
10.2217/epi-2019-0358 · 2020 · External reference
Pharmacology of epitranscriptomic modifications: Decoding the therapeutic potential of RNA modifications in drug resistance
10.1016/j.ejphar.2025.177397 · 2025 · External reference
A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation
10.1016/j.tranon.2017.07.008 · 2017 · External reference
Targeting Clinical Epigenetic Reprogramming for Chemoprevention of Metabolic and Viral Hepatocellular Carcinoma
10.1136/gutjnl-2019-318918 · 2020 · External reference
Ribavirin Restores ESR1 Gene Expression and Tamoxifen Sensitivity in ESR1 Negative Breast Cancer Cell Lines
10.1186/1868-7083-3-8 · 2011 · External reference
Eukaryotic 5-Methylcytosine (m⁵C) RNA Methyltransferases: Mechanisms, Cellular Functions, and Links to Disease
10.3390/genes10020102 · 2019 · External reference
Machine Learning Informs RNA-Binding Chemical Space
10.1002/anie.202211358 · 2023 · External reference
Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs
10.1021/acschembio.6b00001 · 2016 · External reference
Sequence-Based Design of Bioactive Small Molecules That Target Precursor microRNAs
10.1038/nchembio.1452 · 2014 · External reference
RNA-based Therapeutics: An Overview and Prospectus
10.1038/s41419-022-05075-2 · 2022 · External reference
Tapping the RNA World for Therapeutics
10.1038/s41594-018-0054-4 · 2018 · External reference
Lipids and Lipid Derivatives for RNA Delivery
10.1021/acs.chemrev.1c00244 · 2021 · External reference
An Ionizable Lipid Toolbox for RNA Delivery
10.1038/s41467-021-27493-0 · 2021 · External reference
Lipid Nanoparticle Spherical Nucleic Acids for Intracellular DNA and RNA Delivery
10.1021/acs.nanolett.1c01973 · 2021 · External reference
Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer
2021 · External reference
CRISPR-engineered T Cells in Patients With Refractory Cancer
10.1126/science.aba7365 · 2020 · External reference
Cancerous pH-responsive Polycarboxybetaine-coated Lipid Nanoparticle for Smart Delivery of siRNA Against Subcutaneous Tumor Model in Mice
10.1111/cas.15554 · 2022 · External reference
CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook
10.1007/s12672-025-03383-5 · 2025 · External reference
Dissecting the oncogenic properties of essential RNA-modifying enzymes: a focus on NAT10
10.1038/s41388-024-02975-9 · 2024 · External reference
Biosynthesis and bioassays of multifunctional S-adenosylmethionine: A comprehensive review
10.1016/j.cej.2025.164933 · 2025 · External reference
The Diagnostic Value of Lower Glucose Consumption for IDH1 Mutated Gliomas on FDG-PET
2021 · External reference
The Regulation of m⁶A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches
10.3390/cancers15133307 · 2023 · External reference
Reviewing the IDH1 Mutation-Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies
10.1111/cbdd.70102 · 2025 · External reference
The Curious Case of IDH Mutant Acute Myeloid Leukaemia: Biochemistry and Therapeutic Approaches
10.1042/bst20230017 · 2023 · External reference
Targeting Oncometabolism to Maximize Immunotherapy in Malignant Brain Tumors
10.1038/s41388-022-02312-y · 2022 · External reference
Recent Advances of IDH1 Mutant Inhibitor in Cancer Therapy
10.3389/fphar.2022.982424 · 2022 · External reference
The regulation of N⁶-methyladenosine modification in PD-L1-induced anti-tumor immunity
10.1111/imcb.12620 · 2023 · External reference
LRPPRC promotes glycolysis by stabilising LDHA mRNA and its knockdown plus glutamine inhibitor induces synthetic lethality via m(6) A modification in triple-negative breast cancer
10.1002/ctm2.1583 · 2024 · External reference
Targeting intracellular mRNA m(6)A-modifiers in advancing immunotherapeutics
2025 · External reference
The Advances in Epigenetics for Cancer Radiotherapy
10.3390/ijms23105654 · 2022 · External reference
Latest Findings on the Function of Immune Metabolism in Tumor Immunity], Sichuan da xue xue bao
2023 · External reference
A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment
2022 · External reference
Glutamine's double-edged sword: fueling tumor growth and offering therapeutic hope
10.3389/fimmu.2025.1578940 · 2025 · External reference
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies
10.1007/s11684-023-1025-7 · 2023 · External reference
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
10.3390/cancers12061502 · 2020 · External reference
Tumor microenvironment responsive polypeptide-based supramolecular nanoprodrugs for combination therapy
10.1016/j.actbio.2022.04.027 · 2022 · External reference
Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity
2025 · External reference
Copper-doped layered double hydroxides co-deliver proteins/drugs for cascaded chemodynamic/immunotherapy via dual regulation of tumor metabolism
10.1016/j.actbio.2025.02.008 · 2025 · External reference
Macrophage-targeting combination therapy enhances T-DXd-induced tumor regression
10.1016/j.intimp.2025.114378 · 2025 · External reference
METTL3-Driven m⁶A Modification of Cpt1a Gene in High Fat Diet Related Liver Cancer Tumor Macrophages Facilitates Type II Macrophage Differentiation
2025 · External reference
Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
10.3390/cancers13225810 · 2021 · External reference
Metabolic challengers selecting tumor-persistent cells
10.1016/j.tem.2023.11.005 · 2024 · External reference
Metabolic rewiring and communication in cancer immunity
10.1016/j.chembiol.2024.02.001 · 2024 · External reference
Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
10.3390/ijms221910268 · 2021 · External reference
Targeting cholesterol metabolism in tumor and its immune microenvironment: opportunities and challenges
10.1016/j.bbcan.2025.189422 · 2025 · External reference
Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies
10.7150/thno.105276 · 2025 · External reference
Metabolic adaptations in cancer stem cells: A key to therapy resistance
10.1016/j.bbadis.2024.167164 · 2024 · External reference
Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer
10.7150/thno.42523 · 2020 · External reference
Metabolic Plasticity and Cancer Stem Cell Metabolism: Exploring the Glycolysis-OXPHOS Switch as a Mechanism for Resistance and Tumorigenesis
10.1007/s12015-025-10956-y · 2025 · External reference
Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations
10.3389/fcell.2023.1254313 · 2023 · External reference
Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance
10.1089/ars.2022.0088 · 2023 · External reference
Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions
10.1038/s41420-025-02670-y · 2025 · External reference
Manipulation of Mitochondrial Plasticity Changes the Metabolic Competition Between "Foe" and "Friend" During Tumor Malignant Transformation
10.3389/fonc.2020.01692 · 2020 · External reference
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity
10.1158/2159-8290.cd-23-0225 · 2023 · External reference
Persister cell plasticity in tumour drug resistance
10.1016/j.semcdb.2023.11.003 · 2024 · External reference
Cellular adaptation to cancer therapy along a resistance continuum
10.1038/s41586-024-07690-9 · 2024 · External reference
Crosstalk of Eight Types of RNA Modification Regulators Defines Tumor Microenvironments, Cancer Hallmarks, and Prognosis of Lung Adenocarcinoma
2022 · External reference
Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies
10.3389/fcell.2021.777007 · 2021 · External reference
Bone Marrow Mesenchymal Stem Cells Induce Metabolic Plasticity in Estrogen Receptor-Positive Breast Cancer
10.1158/1541-7786.mcr-22-0451 · 2023 · External reference
A micro-metabolic rewiring assay for assessing hypoxia-associated cancer metabolic heterogeneity
2025 · External reference
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance
10.1038/s41392-025-02266-z · 2025 · External reference
On the road to colorectal cancer development: crosstalk between the gut microbiota, metabolic reprogramming, and epigenetic modifications
10.1093/carcin/bgad058 · 2023 · External reference
The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics
10.1038/s41416-025-02969-8 · 2025 · External reference
N(6)-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction
10.7150/thno.52366 · 2021 · External reference
The interplay between m⁶A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications
10.7150/ijbs.60641 · 2021 · External reference
Novel insights into the N 6-methyladenosine modification on circRNA in cancer
10.5772/intechopen.1005693 · 2025 · External reference
Biomarkers related to m⁶A and succinic acid metabolism in papillary thyroid carcinoma
10.1186/s12920-024-01975-8 · 2024 · External reference
Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer, Drug metabolism and disposition: the biological fate of
2020 · External reference
Molecular Features, Biological Behaviors and Clinical Implications of M 5C RNA Methylation Modification Regulators in Gastrointestinal Cancers
10.1080/15384047.2023.2223382 · 2023 · External reference
Epitranscriptomics in Hematopoiesis and Hematologic Malignancies
10.1158/2643-3249.bcd-20-0032 · 2020 · External reference
RNA Modification in Metabolism
10.1002/mco2.70135 · 2025 · External reference
